STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBDDan Turner, Axel Dignaß, Amanda Ricciuto et al.|Gastroenterology|2021Cited by 2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-TargetLaurent Peyrin‐Biroulet, Iris Dotan, Marla C. Dubinsky et al.|The American Journal of Gastroenterology|2015Cited by 1.8k
Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Azathioprine and 6-Mercaptopurine: A Meta-analysisDavid Kotlyar, Gary R. Lichtenstein, James D. Lewis et al.|Clinical Gastroenterology and Hepatology|2014Cited by 405
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsGeert D’Haens, Marc Ferrante, Remo Panaccione et al.|The Lancet|2022Cited by 383
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialMarc Ferrante, Geert D’Haens, Remo Panaccione et al.|The Lancet|2022Cited by 312